Biogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer’s drug, they said Thursday, marking the latest set back for an industry keen to develop treatments for the memory-robbing disease.The decision to discontinue the trials testing drug aducanumab was made after an independent data monitoring committee reported the drug was unlikely to be successful, the companies said.
The recommendation was not based on safety concerns, they added. After dozens of experimental Alzheimer’s drugs have failed in the recent past, there is a desperate need for a treatment that works. The disease is the most common form of dementia that affects nearly 50 million people worldwide and is expected to rise to more than 131 million by 2050, according to Alzheimer’s Disease International.“This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience,” Biogen Chief Executive Officer Michel Vounatsos said.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SABC News Online - 🏆 32. / 51 Read more »